留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

免疫检查点抑制剂相关甲状腺毒症

武凌鸽 徐燕 李乃适

武凌鸽, 徐燕, 李乃适. 免疫检查点抑制剂相关甲状腺毒症[J]. 协和医学杂志, 2021, 12(1): 129-135. doi: 10.3969/j.issn.1674-9081.2020.00.004
引用本文: 武凌鸽, 徐燕, 李乃适. 免疫检查点抑制剂相关甲状腺毒症[J]. 协和医学杂志, 2021, 12(1): 129-135. doi: 10.3969/j.issn.1674-9081.2020.00.004
WU Ling-ge, XU Yan, LI Nai-shi. Thyrotoxicosis Related to Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 129-135. doi: 10.3969/j.issn.1674-9081.2020.00.004
Citation: WU Ling-ge, XU Yan, LI Nai-shi. Thyrotoxicosis Related to Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 129-135. doi: 10.3969/j.issn.1674-9081.2020.00.004

免疫检查点抑制剂相关甲状腺毒症

doi: 10.3969/j.issn.1674-9081.2020.00.004
基金项目: 

国家“十三五”重大新药创制专项子课题“创新药物临床评价示范性平台建设” 2019ZX09734001-002

中国医学科学院医学与健康科技创新工程重大协同创新项目 2017-I2M-1-009

详细信息
    通讯作者:

    李乃适 电话:010-69155073, E-mail:LNS@medmail.com.cn

  • 中图分类号: R979.5; R581

Thyrotoxicosis Related to Immune Checkpoint Inhibitors

Funds: 

"13th Five-Year"National Science and Technology Major Project for New Drugs 2019ZX09734001-002

CAMS Innovation Fund for Medical Sciences 2017-I2M-1-009

More Information
  • 摘要: 免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)是近年来恶性肿瘤治疗领域的一项重大突破。其通过针对T细胞的调节作用,增强抗肿瘤免疫反应,改善恶性肿瘤患者的预后,延长患者生存期,现已获批用于治疗多种肿瘤,但ICIs在应用过程中产生的甲状腺毒症是不容忽视的临床问题。本文对ICIs相关甲状腺毒症的发生机制、临床表现、处理对策等进行综述。
    作者贡献:武凌鸽负责文献检索、数据分析及文章初稿撰写;李乃适、徐燕负责文章初稿修订;李乃适负责文章审校。
    利益冲突  无
  • [1] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12:252-64. doi:  10.1038/nrc3239
    [2] Sharma P, Allison JP. The future of immune checkpoint therapy[J]. Science, 2015, 348:56-61. doi:  10.1126/science.aaa8172
    [3] Momtaz P, Postow MA.Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway[J]. Pharmgenomics Pers Med, 2014, 7:357-365. http://www.tandfonline.com/servlet/linkout?suffix=CIT0001&dbid=8&doi=10.1517%2F14740338.2015.1085969&key=25484597
    [4] Postow MA, Callahan MK, Wolchok JD. Immune Check-point Blockade in Cancer Therapy[J]. J Clin Oncol, 2015, 33:1974-1982. doi:  10.1200/JCO.2014.59.4358
    [5] Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al.Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis[J]. JAMA Oncol, 2018, 4:173-182. doi:  10.1001/jamaoncol.2017.3064
    [6] Surks MI, Chopra IJ, Mariash CN, et al.American Thyroid Association guidelines for use of laboratory tests in thyroid disorders[J]. JAMA, 1990, 263:1529-1532. doi:  10.1001/jama.1990.03440110095035
    [7] Sharma P, Hu-Lieskovan S, Wargo JA, et al.Primary, Adaptive, and Acquired Resistance to Cancer Immuno-therapy[J]. Cell, 2017, 168:707-723. doi:  10.1016/j.cell.2017.01.017
    [8] Reeves E, James E.Antigen processing and immune regulation in the response to tumours[J]. Immunology, 2017, 150:16-24. doi:  10.1111/imm.12675
    [9] Harding FA, McArthur JG, Gross JA, et al.CD28-media-ted signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones[J]. Nature, 1992, 356:607-609. doi:  10.1038/356607a0
    [10] Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity[J]. Nat Rev Immunol, 2004, 4:336-347. doi:  10.1038/nri1349
    [11] Fecher LA, Agarwala SS, Hodi FS, et al. Ipilimumab and its toxicities: a multidisciplinary approach[J]. Oncologist, 2013, 18:733-743. doi:  10.1634/theoncologist.2012-0483
    [12] Brahmer JR, Lacchetti C, Thompson JA. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary[J]. J Oncol Pract, 2018, 14:247-249. doi:  10.1200/JOP.18.00005
    [13] Barroso-Sousa R, Ott PA, Hodi FS, et al. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management[J]. Cancer, 2018, 124:1111-1121. doi:  10.1002/cncr.31200
    [14] Delivanis DA, Gustafson MP, Bornschlegl S, et al.Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms[J]. J Clin Endocrinol Metab, 2017, 102:2770-2780. doi:  10.1210/jc.2017-00448
    [15] Angell TE, Min L, Wieczorek TJ, et al.Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma[J]. Genes Dis, 2018, 5:46-48. doi:  10.1016/j.gendis.2017.11.002
    [16] Yamauchi I, Sakane Y, Fukuda Y, et al.Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study[J]. Thyroid, 2017, 27:894-901. doi:  10.1089/thy.2016.0562
    [17] Inoue H, Park JH, Kiyotani K, et al. Intratumoral expres-sion levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma[J]. Oncoimmunology, 2016, 5:e1204507. doi:  10.1080/2162402X.2016.1204507
    [18] Scott ES, Long GV, Guminski A, et al.The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma[J].Eur J Endocrinol, 2018, 178:173-180. doi:  10.1530/EJE-17-0810
    [19] Morganstein DL, Lai Z, Spain L, et al. Thyroid abnor-malities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma[J]. Clin Endocrinol (Oxf), 2017, 86:614-620. doi:  10.1111/cen.13297
    [20] Lee H, Hodi FS, Giobbie-Hurder A, et al. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy[J]. Cancer Immunol Res, 2017, 5:1133-1140. doi:  10.1158/2326-6066.CIR-17-0208
    [21] Guaraldi F, La Selva R, Samà MT, et al. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution[J]. J Endocrinol Invest, 2018, 41:549-556. doi:  10.1007/s40618-017-0772-1
    [22] Yamazaki H, Iwasaki H, Yamashita T, et al. Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction[J]. In Vivo, 2017, 31:1225-1228.
    [23] Orlov S, Salari F, Kashat L, et al. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies[J]. J Clin Endocrinol Metab, 2015, 100:1738-1741. doi:  10.1210/jc.2014-4560
    [24] O'Malley G, Lee HJ, Parekh S, et al. Rapid Evolution of Thyroid Dysfunction in Patients Treated with Nivolumab[J]. Endocr Pract, 2017, 23:1223-1231. doi:  10.4158/EP171832.OR
    [25] de Filette J, Jansen Y, Schreuer M, et al. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab[J]. J Clin Endocrinol Metab, 2016, 101:4431-4439. doi:  10.1210/jc.2016-2300
    [26] Kimbara S, Fujiwara Y, Iwama S, et al.Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab[J].Cancer Sci, 2018, 109:3583-3590. doi:  10.1111/cas.13800
    [27] Osorio JC, Ni A, Chaft JE, et al.Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J]. Ann Oncol, 2017, 28:583-589. doi:  10.1093/annonc/mdw640
    [28] Kavvoura FK, Akamizu T, Awata T, et al. Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis[J]. J Clin Endocrinol Metab, 2007, 92:3162-3170. doi:  10.1210/jc.2007-0147
    [29] Azmat U, Liebner D, Joehlin-Price A, et al.Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma[J].Case Rep Endocrinol, 2016:2087525. http://pubmedcentralcanada.ca/pmcc/articles/PMC4737013/
    [30] Heward JM, Allahabadia A, Armitage M, et al.The development of Graves' disease and the CTLA-4 gene on chromosome 2q33[J]. J Clin Endocrinol Metab, 1999, 84:2398-2401. http://www.ncbi.nlm.nih.gov/pubmed/10404810
    [31] Daroszewski J, Pawlak E, Karabon L, et al. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms[J]. Eur J Endocrinol, 2009, 161:787-793. doi:  10.1530/EJE-09-0600
    [32] Ting WH, Chien MN, Lo FS, et al.Association of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4) Gene Polymorphisms with Autoimmune Thyroid Disease in Children and Adults: Case-Control Study[J]. PLoS One, 2016, 11:e0154394. doi:  10.1371/journal.pone.0154394
    [33] Vaidya B, Imrie H, Perros P, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers suscepti-bility to thyroid associated orbitopathy[J]. Lancet, 1999, 354:743-744. doi:  10.1016/S0140-6736(99)01465-8
    [34] Buzzetti R, Nisticò L, Signore A, et al. CTLA-4 and HLA gene susceptibility to thyroid-associated orbitopathy[J]. Lancet, 1999, 354:1824. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=2212292&site=ehost-live
    [35] Villanueva R, Inzerillo AM, Tomer Y, et al. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology[J]. Thyroid, 2000, 10:791-798. doi:  10.1089/thy.2000.10.791
    [36] Allahabadia A, Heward JM, Nithiyananthan R, et al.MHC class Ⅱ region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease[J]. Lancet, 2001, 358:984-985. doi:  10.1016/S0140-6736(01)06125-6
    [37] Kotsa K, Watson PF, Weetman AP. A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism[J].Clin Endocrinol (Oxf), 1997, 46:551-554. doi:  10.1046/j.1365-2265.1997.1710996.x
    [38] Bednarczuk T, Gopinath B, Ploski R, et al.Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack?[J]. Clin Endocrinol (Oxf), 2007, 67:3-19. doi:  10.1111/j.1365-2265.2007.02854.x
    [39] Mitchell AL, Cordell HJ, Soemedi R, et al.Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and Graves' disease susceptibility[J]. J Clin Endocrinol Metab, 2009, 94:5139-5145. doi:  10.1210/jc.2009-1404
    [40] Hayashi M, Kouki T, Takasu N, et al.Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients[J]. Eur J Endocrinol, 2008, 158:817-822. doi:  10.1530/EJE-07-0649
    [41] de Filette J, Andreescu CE, Cools F, et al. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors[J].Horm Metab Res, 2019, 51:145-156. doi:  10.1055/a-0843-3366
    [42] Gan EH, Mitchell AL, Plummer R, et al.Tremelimumab-Induced Graves Hyperthyroidism[J]. Eur Thyroid J, 2017, 6:167-170. doi:  10.1159/000464285
    [43] Brancatella A, Viola N, Brogioni S, et al. Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature[J]. Eur Thyroid J, 2019, 8:192-195. doi:  10.1159/000501824
    [44] Iadarola C, Croce L, Quaquarini E, et al. Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis[J]. Front Endocrinol (Lausanne), 2019, 9:813. doi:  10.3389/fendo.2018.00813
    [45] Min L, Vaidya A, Becker C.Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy[J]. Eur J Endocrinol, 2011, 164:303-307. doi:  10.1530/EJE-10-0833
    [46] Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plast Reconstr Surg[J]. Ophthalmic Plast Reconstr Surg, 2011, 27:e87-e88. doi:  10.1097/IOP.0b013e3181ef72a1
    [47] McElnea E, Ní Mhéalóid A, Moran S, et al. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab[J]. Orbit, 2014, 33:424-427. doi:  10.3109/01676830.2014.949792
    [48] Park ESY, Rabinowits G, Hamnvik OR, et al. A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy[J]. J AAPOS, 2018, 22:310-312. doi:  10.1016/j.jaapos.2018.01.006
    [49] Campredon P, Imbert P, Mouly C, et al. Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment[J]. Eur Thyroid J, 2018, 7:84-87. doi:  10.1159/000485742
    [50] Hudzik B, Zubelewicz-Szkodzinska B. Radiocontrast-induced thyroid dysfunction: is it common and what should we do about it?[J]. Clin Endocrinol (Oxf), 2014, 80:322-327. doi:  10.1111/cen.12376
    [51] Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020[J].J Natl Compr Canc Netw, 2020, 18:230-241. doi:  10.6004/jnccn.2020.0012
    [52] Peiró I, Palmero R, Iglesias P, et al.Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes[J]. Endocrine, 2019, 64:605-613. doi:  10.1007/s12020-019-01871-7
    [53] Borodic GE, Hinkle D.Ipilimumab-induced orbital inflamma-tion resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression[J]. Ophthalmic Plast Reconstr Surg, 2014, 30:83. http://www.ncbi.nlm.nih.gov/pubmed/24398505
    [54] Yu C, Chopra IJ, Ha E.A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis[J]. Endocrinol Diabetes Metab Case Rep, 2015:140092. http://pubmedcentralcanada.ca/pmcc/articles/PMC4330494/?lang=fr
    [55] Yonezaki K, Kobayashi T, Imachi H, et al. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report[J]. J Med Case Rep, 2018, 12:171. doi:  10.1186/s13256-018-1708-x
    [56] McMillen B, Dhillon MS, Yong-Yow S. A rare case of thyroid storm[J]. BMJ Case Rep, 2016: 10.1136/bcr-2016-214603.
  • 加载中
计量
  • 文章访问数:  264
  • HTML全文浏览量:  89
  • PDF下载量:  18
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-04-13
  • 录用日期:  2020-05-14
  • 网络出版日期:  2020-08-14
  • 刊出日期:  2021-01-30

目录

    /

    返回文章
    返回